

## Special Issue

# Role of Adipose Organ in Metabolism and Disease

### Message from the Guest Editor

Obesity is the fifth leading cause of death worldwide. At the end of 18th Century, the Italian anatomist Gian Battista Morgagni defined illness as a condition in which a pathologic organ can be demonstrated. White adipose tissue of obese animals and humans is inflamed by a chronic low-grade inflammation sustained mainly by macrophages. These cells are scavengers attracted in the obese adipose tissues by remnants derived from death of hypertrophic white adipocytes. Together with white adipocytes that store lipids for metabolic needs, there are also brown adipocytes with different physiology: they burn lipids for thermogenesis. Both adipocytes are contained together into a dissectible structure fulfilling the definition of organ: dissectible structure formed at least by two different tissues cooperating each other. In this issue the human adipose organ and its implication for obesity is described. Several metabolic and pathologic aspects deriving and connected to this new concept are also described in this issue.

---

### Guest Editor

Prof. Dr. Saverio Cinti

Scientific Director of Center of Obesity, Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/131137](https://mdpi.com/si/131137)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).